Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.26 -4.34%

-$0.11 today

Market cap
$426.53M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 2.16M

Average 3.07M

OVID Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Ovid Therapeutics Inc.NASDAQ: OVID

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $130K a year earlier. Trailing-twelve-month revenue was $7.12M. Over 3 fiscal years it compounded at +69.0% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 9 analysts of $805K (-88.9%) for the fiscal year ending Dec 2026, a slowdown from the +1181.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$7.25M+1181.3% YoY
LTMMar 2026
$7.12M+1199.6% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%-99.7%+0.3 pp
1 year+1181.3%-88.9%-1270.2 pp
3-year CAGR+69.0%+28.5%-40.5 pp
5-year CAGR+52.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
7.25M USD
Year-over-year change
+1181.3%
4-year CAGR
-56.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How OVID compares with its peers on the latest reported figures

  • OVID's LTM Mar 2026 revenue of $7.12M is the 7th highest of the 11 companies compared; the peer median is $23.31M.
  • Its year-over-year change of +1199.6% is the highest of 8, against a peer median of -32.3%.
  • Over three fiscal years its annual growth of +69.0% compares with a peer median of +60.3%.
OVID Competitors Peer median
Revenue for OVID and competitors
Company Period LTM YoY 3-year CAGR
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$669.43M +13.3%+22.8%
MGTXMeiraGTx Holdings plcLTM Mar 2026$79.76M +131.1%+72.3%
WVEWave Life Sciences Ltd.LTM Mar 2026$71.8M -31.6%+127.1%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$36.49M -45.5%-0.4%
STOKStoke Therapeutics, Inc.LTM Mar 2026$32.08M -83.2%+145.9%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$14.54M —+60.3%
OVIDOvid Therapeutics Inc.LTM Mar 2026$7.12M +1199.6%+69.0%
TSHATaysha Gene Therapies, Inc.LTM Jun 2026$5.49M -32.3%+57.5%
NGNENeurogene Inc.LTM Mar 2026$0 -100.0%—
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$0 ——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$0 ——
Peer median (excluding OVID) $23.31M-32.3%+60.3%

Competitors are the stored peer set for OVID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue208.38M1.5M392K566K7.25M
Cost of Revenue0000300K
Gross Profit208.38M1.5M392K566K6.95M
Gross Margin100.0%100.0%100.0%100.0%95.9%
Research & Development46.94M24.62M28.59M36.77M25.58M
Selling, General & Admin37.23M32.43M29.59M25.68M24.11M
Operating Expenses84.17M57.05M59.67M62.45M49.39M
Depreciation & Amortization237.08K1.38M568K613K300K
EBITDA124.45M(54.17M)(57.01M)(57.77M)(17.11M)
EBITDA Margin59.7%-3604.5%-14544.1%-10207.1%-236.0%
Operating Income124.21M(55.55M)(59.28M)(61.89M)(42.44M)
Operating Margin59.6%-3696.4%-15122.7%-10933.7%-585.2%
Interest Income004.9M3.9M0
Interest Expense00000
Other Income / Expenses(45.69K)1.38M6.94M35.45M25.03M
Income Before Tax124.16M(54.17M)(52.34M)(26.43M)(17.41M)
Pre-Tax Margin59.6%-3604.7%-13351.8%-4670.1%-240.1%
Income Tax Expense1.33M0000
Net Income122.83M(54.17M)(52.34M)(26.43M)(17.41M)
Net Margin58.9%-3604.7%-13351.8%-4670.1%-240.1%
EPS (Basic)1.78(0.77)(0.74)(0.37)(0.24)
EPS (Diluted)1.76(0.77)(0.74)(0.37)(0.24)
Weighted Avg Shares67.48M70.43M70.58M70.91M73.74M
Weighted Avg Shares (Diluted)68.07M70.43M70.58M70.91M73.74M

Ovid Therapeutics Inc.

NASDAQ:OVID

Intrinsic Alpha fair value

Locked

Current Price

$2.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.